Boehringer’s lung drug Spiriva, approved for chronic obstructive pulmonary disease (COPD) and asthma, generated net sales of 2.4 billion euros, down 11.4% compared with last year, which the ...

As the EU patent expires on its flagship respiratory diseases product, Spiriva, Boehringer Ingelheim is looking to newer diabetes and respiratory drugs under the leadership of a new CEO.

Tiotropium (Spiriva Respimat) and olodaterol (Striverdi Respimat) are bronchodilator drugs that come in a soft mist. Stiolto Respimat combines the drugs. More of the medication gets into your ...